Page 17 - Confidence Interval News Today

Despite access to care and health insurance, Hispanic and non-Hispanic Black individuals with diabetes experience poorer glycemic control compared to non-Hispanic White counterparts, revealing persistent racial disparities in healthcare.

Neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo reduced the risk of disease recurrence, progression or death by 42% in patients with resectable non-small cell lung...

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.

In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo1 CheckMate -76K marks the fifth Opdivo-based...

Bristol Myers Squibb announced that Opdivo was approved by the U.S. Food and Drug Administration for the adjuvant treatment of adult and pediatric patients 12 years and older with completely...

In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo1CheckMate -76K marks the fifth Opdivo-based indication in earlier stages of cancer, in the U.S.1Opdivo is the only PD-1 inhibitor that is indicated as an adjuvant treatment...

Talquetamab is a bispecific T-cell engaging antibody that binds to CD3 The Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that

Alex Hajduczok, MD, provides perspective on the new GUIDE-HF trial data presented at HFSA 2023.

1. In this randomized controlled trial, complete revascularization reduced the risk of myocardial infarction, stroke, or ischemia-driven revascularization at one year in patients with myocardial infarction compared to culprit lesion revascularization. 2. There was no difference in safety outcomes, including acute kidney injury, stroke, or bleeding, between groups. Evidence Rating Level: 1 (Excellent) Study Rundown: The decision

1. In this randomized controlled trial, ferric carboxymaltose was not superior to placebo in improving death and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF) and concurrent iron deficiency. 2. Ferric carboxymaltose was safe and improved six-minute walk distance. Evidence Rating Level: 1 (Excellent) Study Rundown: Iron deficiency is a common complication